<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00715481</url>
  </required_header>
  <id_info>
    <org_study_id>DNSG-SID 0601</org_study_id>
    <nct_id>NCT00715481</nct_id>
  </id_info>
  <brief_title>Renal Insufficiency And Cardiovascular Events</brief_title>
  <acronym>RIACE</acronym>
  <official_title>Reduced Estimated Glomerular Filtration Rate (eGFR)and Prediction of Cardiovascular Disease and Renal Outcome in Subjects With Type 2 Diabetes: Italian Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diabetic Nephropathy Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Italian Society of Diabetology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Diabetic Nephropathy Study Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reduced glomerular filtration rate (GFR) has been recently shown to be a powerful predictor&#xD;
      of cardiovascular morbidity and mortality in the general population, independent of&#xD;
      traditional cardiovascular risk factors.&#xD;
&#xD;
      This observational study is aimed at assessing the association of reduced estimated GFR with&#xD;
      cardiovascular morbidity and mortality in a large italian population (at least 15,000&#xD;
      subjects) of type 2 diabetic outpatients over a 4-year follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Reduced GFR has been recently shown to be a powerful predictor of cardiovascular morbidity&#xD;
      and mortality in the general population, independent of traditional cardiovascular risk&#xD;
      factors. Since type 2 diabetic patients show increased cardiovascular morbidity and mortality&#xD;
      as compared with the general population, the identification of predictors of cardiovascular&#xD;
      disease in these patients is of fundamental importance for clinical purposes. One of these&#xD;
      predictors is increased urinary albumin excretion rate, which is associated with an increased&#xD;
      risk of cardiovascular disease more than of end-stage renal disease. However, a growing body&#xD;
      of evidence indicates that a significant proportion of normoalbuminuric diabetic patients,&#xD;
      particularly with type 2 diabetes, may exhibit reduced GFR. It is currently unknown the&#xD;
      predictive role of this abnormality toward cardiovascular events and death, independent of&#xD;
      albuminuria and other known risk factors, in the diabetic population.&#xD;
&#xD;
      This observational study is aimed at assessing the association of reduced estimated GFR with&#xD;
      cardiovascular morbidity and mortality in a large italian population (at least 15,000&#xD;
      subjects) of type 2 diabetic nondialytic outpatients over a 4-year follow-up.&#xD;
&#xD;
      Secondary endpoints are to assess in this population:&#xD;
&#xD;
        -  the prevalence and incidence of reduced GFR, as classified according to the National&#xD;
           Kidney Foundation criteria, and its association with traditional cardiovascular risk&#xD;
           factors;&#xD;
&#xD;
        -  the prevalence, incidence and cardiovascular predictivity of micro and macroalbuminuria.&#xD;
&#xD;
      Patients will be recruited from electronic records of 20 italian outpatients diabetic&#xD;
      clinics.&#xD;
&#xD;
      Routine anamnestic, clinical, laboratory and instrumental data will be recorded at baseline&#xD;
      and over 4 years to obtain information about:&#xD;
&#xD;
        -  renal function (albumin/creatinine ratio, serum creatinine with estimation of glomerular&#xD;
           filtration rate [eGFR]);&#xD;
&#xD;
        -  cardiovascular risk factors (smoking, physical activity, family history of diabetes,&#xD;
           dyslipidemia, hypertension and cardiovascular disease, BMI and waist circumference,&#xD;
           total, LDL, HDL and non-HDL cholesterol, triglycerides, arterial blood pressure and&#xD;
           HbA1c);&#xD;
&#xD;
        -  current glucose-, lipid- and blood pressure-lowering and anti-platelet or anti-coagulant&#xD;
           treatment;&#xD;
&#xD;
        -  other illnesses;&#xD;
&#xD;
        -  cardiovascular events (myocardial infarction, stroke, lower limb&#xD;
           ulcer/gangrene/amputation and coronary, carotid and lower limb revascularization,&#xD;
           endovascular/surgical) and deaths.&#xD;
&#xD;
      These data will be derived from the electronic database of each participating center.&#xD;
&#xD;
      Laboratory analyses will be performed in each centre laboratory after proper standardization&#xD;
      of analytical techniques.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>cardiovascular morbidity and mortality</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>eGFR, as classified according to the National Kidney Foundation criteria</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>micro/macroalbuminuria</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>traditional cardiovascular risk factors</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">15628</enrollment>
  <condition>Cardiovascular Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Outpatients clinics&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        type 2 diabetes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        dyalisis or renal transplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Pugliese, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetic Nephropathy Study Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Solini, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Diabetic Nephropathy Study Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mazzoni Hospital, Division of Diabetology</name>
      <address>
        <city>Ascoli Piceno</city>
        <zip>63100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Hospital, Division of Endocrinology</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti di Bergamo, Division of Diabetology</name>
      <address>
        <city>Bergamo</city>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monserrato Hospital, Division of Diabetology</name>
      <address>
        <city>Cagliari</city>
        <zip>09042</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Domini Hospital, Division of Internal Medicine</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Hospital, Division of Endocrinology</name>
      <address>
        <city>Foggia</city>
        <zip>71100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Maria Goretti Hospital, Division of Diabetology</name>
      <address>
        <city>Latina</city>
        <zip>04100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico - Maggiore Hospital, Division of Endocrinology and Diabetology</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Giuseppe Hospital, Division of Endocrinology</name>
      <address>
        <city>Milano</city>
        <zip>20123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Raffaele Hospital</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Paolo Hospital, Division of Internal Medicine</name>
      <address>
        <city>Milano</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Luigi Gonzaga Hospital, Division of Diabetes and Metabolic Diseases</name>
      <address>
        <city>Orbassano-Torino</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Hospital, Division of Diabetology</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cisanello Hospital, Divisions of Diabetology</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Chiara Hospital, Division of Internal Medicine</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Hospital, Division of Internal Medicine</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sant'Andrea Hospital, Division of Diabetology</name>
      <address>
        <city>Rome</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Le Scotte, Division of Diabetology</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Le Molinette - San Giovanni Battista Hospital, Division of Diabetology</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maggiore Hospital, Division of Endocrinology and Metabolic Diseases</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.renediabete.it</url>
    <description>online database</description>
  </link>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>July 10, 2008</study_first_submitted>
  <study_first_submitted_qc>July 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2008</study_first_posted>
  <last_update_submitted>February 9, 2015</last_update_submitted>
  <last_update_submitted_qc>February 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Diabetic Nephropathy Study Group</investigator_affiliation>
    <investigator_full_name>Giuseppe Pugliese</investigator_full_name>
    <investigator_title>Professor of Endocrinology and Metabolism</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Cardiovascular disease</keyword>
  <keyword>Diabetic Nephropathy</keyword>
  <keyword>Glomerular filtration rate</keyword>
  <keyword>Albuminuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

